Enovis (NYSE:ENOV) Director Angela Lalor Acquires 870 Shares of Stock

Enovis Corporation (NYSE:ENOV) Director Angela Lalor acquired 870 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was purchased at an average price of $28.86 per share, for a total transaction of $25,108.20. Following the completion of the transaction, the director owned 33,243 shares in the company, valued at $959,392.98. The trade was a 2.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Enovis Stock Performance

ENOV traded down $0.92 during trading on Thursday, reaching $27.63. The company’s stock had a trading volume of 1,153,270 shares, compared to its average volume of 1,886,113. Enovis Corporation has a 52-week low of $16.70 and a 52-week high of $31.81. The company’s fifty day moving average price is $20.36 and its 200-day moving average price is $23.19. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 8.45 and a beta of 1.31. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The business had revenue of $558.73 million for the quarter, compared to analysts’ expectations of $557.12 million. During the same period in the prior year, the company posted $0.75 EPS. The business’s revenue for the quarter was up 1.8% on a year-over-year basis. On average, equities analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enovis

A number of large investors have recently bought and sold shares of ENOV. Paradigm Capital Management Inc. NY increased its position in Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after buying an additional 732,917 shares in the last quarter. Private Management Group Inc. raised its holdings in shares of Enovis by 31.3% in the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock worth $32,748,000 after acquiring an additional 427,347 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock worth $24,430,000 after acquiring an additional 287,687 shares during the last quarter. Front Street Capital Management Inc. lifted its position in shares of Enovis by 106.1% in the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after acquiring an additional 384,124 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its position in shares of Enovis by 130.8% in the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after acquiring an additional 342,556 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

ENOV has been the topic of several research analyst reports. Needham & Company LLC boosted their price target on Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. BMO Capital Markets set a $27.00 price objective on Enovis in a report on Tuesday, September 1st. Citizens Jmp decreased their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research report on Wednesday, September 2nd. Finally, Citigroup reissued a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and a consensus target price of $38.62.

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.